AB2 Bio Completes Enrolment for Phase 3 Study of Tadekinig Alfa, a Novel Therapy for Primary Monogenic IL-18 Driven HLH
AB2 Bio Ltd. has completed enrolling participants in its Phase 3 study of Tadekinig alfa, a treatment for primary monogenic IL-18 driven HLH, an ultra-rare and life-threatening condition affecting chi ...